semaglutide period changes and Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial Understanding the Impact of Weight

Injectable semaglutide is the more established option

These methods bypass the digestive system, allowing for greater absorption and immediate availability in the bloodstream

(FDA, Food and Drug Administration) (EMA, European Medicines Agency) 2 7 1 ( , , , , , )

doi: 10.1139/o96-049 31 ChamberlainLHShipstonMJ

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for managing type 2 diabetes and, at higher doses, for chronic weight management in adults with obesity or overweight with weight-related comorbidities

Stricter oversight of unauthorized GLP-1 versions may help CPSE:NOVO B maintain pricing power and brand recognition in a crowded field